Registry for Invasive and Non-invasive Anatomical Assessment and Outcome of Coronary Artery Anomalies
Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Jul 16, 2020
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding a condition known as anomalous coronary artery origin (ACAOS), which involves the abnormal location or path of coronary arteries. While most people with ACAOS do not experience significant health issues, some variations can lead to serious heart problems. The study aims to gather information about different diagnostic methods, such as advanced imaging techniques, to better evaluate and treat patients with this condition. By using specialized tests during heart imaging, researchers hope to learn how the structure of these arteries affects blood flow and what the best treatment options are.
To participate in this study, you need to be at least 18 years old and have a diagnosis of coronary artery anomalies that require testing. This trial is open to all genders, and there are no specific exclusions based on other health conditions. If you join, you can expect to undergo various imaging tests to assess your heart's anatomy and blood flow, which will help doctors determine the most appropriate care for your condition. Your involvement will contribute to important research aimed at improving the understanding and management of coronary artery anomalies.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years.
- • CAA with a clinically indicated testing (noninvasive and/or invasive measurement) at our institution
- • Informed consent
- Exclusion Criteria:
- • - None
About Insel Gruppe Ag, University Hospital Bern
Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bern, , Switzerland
Zürich, , Switzerland
Patients applied
Trial Officials
Christoph Gräni, MD PhD
Principal Investigator
Inselspital, Bern University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials